

REPORT ID AF-2026-493145	VERIFICATION CODE V7GC-SADN	CLIENT China Peptide Source	STATUS ACTIVE
PRODUCT Tirzepatide 30 mg	BATCH / LOT TIRZ-32Y4	SAMPLE RECEIVED Jul 28, 2026	ANALYSIS DATE Jul 30, 2026


CORE ANALYTICAL PANEL

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Tirzepatide - Purity	RP-HPLC	99.63%	≥99.00%	Conforms
Tirzepatide - Mass Identity	LC-MS	4813.0 Da	4813.0 ± 2 Da	Conforms
Net Content Quantity	Gravimetric	30.044 mg	30 mg Target	Measured

BIOSAFETY & SCREENING

SAFETY TEST	METHOD	OBSERVED LEVEL	LIMIT	STATUS
Endotoxin Assay (LAL)	LAL	0.269 EU/mg	≤ 5.0 EU/mg	Pass
Heavy Metal Screen (ICP-MS)	ICP-MS	0.046 ppm	< 0.1 ppm	Pass

RP-HPLC CHROMATOGRAM



Column: C18 Reverse-Phase (4.6 × 150 mm, 3.5 μm) Flow Rate: 1.0 mL/min Wavelength: 214 nm

VERIFICATION

V7GC-SADN

<https://analyticalformulations.com/verify/V7GC-SADN>

Lab ID: AFL-001 · FormuVerify™



Scan to verify certificate